// App-Quantinova.ai

: The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time

Researchers

Presenter

  • David A Lipson

Principal Investigators

  • Gerard Criner

  • Mark Dransfield

  • David Halpin

  • Meilan Han

  • C. Elaine Jones

  • Sally Kilbride

  • Peter Lange

  • David Lomas

  • Fernando Martinez

  • Holly Quasny

  • David Singh

  • Robert Wise

Medical Centers

  • GSK and Perelman School of Medicine, University of Pennsylvania, Collegeville and Philadelphia, PA, United States.

  • Lewis Katz School of Medicine at Temple University, Philadelpha , United States of America

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, United States,

  • Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • GlaxoSmithKline, Research Triangle Park, NC, United States.

  • GlaxoSmithKline, Stockley Park, United Kingdom

  • Department of Biology, University of Copenhagen, Copenhagen, Denmark

  • UCL Respiratory, University College London, London, United Kingdom

  • ARUK Centre for Epidemiology, CfMR, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom

  • Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America

Locations

  • United States

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02164513

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved